Royal Bank of Canada’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$65.2M Buy
510,065
+18,452
+4% +$2.3M 0.01% 800
2025
Q4
$59.9M Buy
491,613
+49,118
+11% +$5.63M 0.01% 859
2025
Q3
$44.3M Sell
442,495
-10,907
-2% -$982K 0.01% 1084
2025
Q2
$37.6M Buy
453,402
+61,986
+16% +$4.95M 0.01% 1104
2025
Q1
$31.7M Sell
391,416
-101,176
-21% -$9.04M 0.01% 1020
2024
Q4
$44.4M Sell
492,592
-453,293
-48% -$43.9M 0.01% 891
2024
Q3
$93.5M Sell
945,885
-73,434
-7% -$7.21M 0.02% 575
2024
Q2
$94.5M Sell
1,019,319
-59,142
-5% -$5.3M 0.02% 536
2024
Q1
$102M Buy
1,078,461
+349,519
+48% +$32.4M 0.02% 514
2023
Q4
$65.1M Sell
728,942
-32,825
-4% -$2.44M 0.02% 672
2023
Q3
$55.6M Buy
761,767
+176,631
+30% +$14.1M 0.02% 655
2023
Q2
$48.7M Sell
585,136
-23,549
-4% -$1.97M 0.01% 710
2023
Q1
$46.4M Sell
608,685
-34,171
-5% -$2.84M 0.01% 710
2022
Q4
$53.4M Sell
642,856
-11,892
-2% -$963K 0.02% 660
2022
Q3
$51.9M Buy
654,748
+134,852
+26% +$11.4M 0.02% 621
2022
Q2
$38.6M Sell
519,896
-97,501
-16% -$7.32M 0.01% 767
2022
Q1
$55.5M Buy
617,397
+65,463
+12% +$6.05M 0.01% 699
2021
Q4
$61.8M Buy
551,934
+135,797
+33% +$16.4M 0.01% 725
2021
Q3
$52.3M Buy
416,137
+47,516
+13% +$6.12M 0.01% 721
2021
Q2
$49.9M Buy
368,621
+8,870
+2% +$1.17M 0.01% 759
2021
Q1
$48.8M Sell
359,751
-46,579
-11% -$6.97M 0.01% 723
2020
Q4
$57.2M Sell
406,330
-335,362
-45% -$43M 0.02% 650
2020
Q3
$82.6M Sell
741,692
-34,834
-4% -$3.91M 0.03% 444
2020
Q2
$86.9M Sell
776,526
-57,029
-7% -$5.62M 0.03% 403
2020
Q1
$64.6M Buy
833,555
+354,685
+74% +$31.4M 0.03% 424
2019
Q4
$45.5M Sell
478,870
-375,340
-44% -$32.5M 0.02% 674
2019
Q3
$65.1M Buy
854,210
+107,891
+14% +$8.97M 0.03% 496
2019
Q2
$65.5M Buy
746,319
+250,476
+51% +$21.4M 0.03% 483
2019
Q1
$44.9M Sell
495,843
-134,332
-21% -$11.4M 0.02% 617
2018
Q4
$45.2M Buy
630,175
+6,465
+1% +$521K 0.02% 559
2018
Q3
$59.8M Buy
623,710
+65,143
+12% +$6.32M 0.02% 513
2018
Q2
$53.2M Sell
558,567
-9,413
-2% -$865K 0.02% 535
2018
Q1
$49.8M Buy
567,980
+134,293
+31% +$12.3M 0.02% 589
2017
Q4
$36.8M Sell
433,687
-37,306
-8% -$3.13M 0.02% 765
2017
Q3
$40.8M Sell
470,993
-7,187
-2% -$576K 0.02% 665
2017
Q2
$36.9M Buy
478,180
+130,273
+37% +$9.24M 0.02% 682
2017
Q1
$24.1M Sell
347,907
-78,043
-18% -$5.24M 0.01% 909
2016
Q4
$25.2M Sell
425,950
-35,164
-8% -$2.17M 0.01% 897
2016
Q3
$30.6M Sell
461,114
-10,885
-2% -$673K 0.02% 743
2016
Q2
$25.5M Buy
471,999
+177,607
+60% +$9.73M 0.02% 793
2016
Q1
$15.2M Sell
294,392
-34,984
-11% -$1.82M 0.01% 1113
2015
Q4
$23.1M Buy
329,376
+213,536
+184% +$14.6M 0.02% 860
2015
Q3
$7.21M Sell
115,840
-274,610
-70% -$21.6M 0.01% 1359
2015
Q2
$32.8M Buy
390,450
+10,107
+3% +$786K 0.02% 567
2015
Q1
$28.6M Buy
380,343
+322,794
+561% +$22.5M 0.02% 632
2014
Q4
$3.58M Sell
57,549
-11,181
-16% -$637K ﹤0.01% 1875
2014
Q3
$3.57M Buy
68,730
+12,057
+21% +$615K ﹤0.01% 1872
2014
Q2
$2.91M Sell
56,673
-14,880
-21% -$671K ﹤0.01% 2022
2014
Q1
$3.4M Buy
71,553
+13,230
+23% +$677K ﹤0.01% 1858
2013
Q4
$2.53M Sell
58,323
-59,235
-50% -$2.45M ﹤0.01% 2116
2013
Q3
$5.06M Sell
117,558
-45,939
-28% -$1.86M ﹤0.01% 1581
2013
Q2
$5.68M Buy
+163,497
New +$5.75M ﹤0.01% 1372

Other funds holding XBI

Royal Bank of Canada's XBI Position: Q1 2026 in Review

Royal Bank of Canada increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3.8% in Q1 2026, buying an estimated $2.3M and bringing the position to 510,065 shares worth $65.2M. The position accounts for 0.01% of the portfolio, ranked #800.

Royal Bank of Canada first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $102M in Q1 2024. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Royal Bank of Canada held 510,065 shares of State Street SPDR S&P Biotech ETF worth $65.2M as of Q1 2026.
  • Royal Bank of Canada bought 18,452 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $2.3M.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #800 holding.
  • Royal Bank of Canada first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's State Street SPDR S&P Biotech ETF position peaked at $102M in Q1 2024.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.